Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Acurx's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin- Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).
Company Profile
Latest Presentation
Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”
View This Presentation
Industry Classifications
Sector:
Pharmaceuticals
Industry:
Healthcare
NAICS:
Pharmaceutical and Medicine Manufacturing (32541)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
In-Site Communications
Lisa Wilson
Company Contact
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305